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Generally, the causation of a complex disease involves joint
deregulation of multiple biological processes, instead of isolated
disruption of some processes [1]. Therefore, understanding the
mechanisms of functions coordinately contributing to a disease is
important for studying the disease. In traditional functional genomic
researches, usually based on Gene Ontology (GO) [2], a list of
interesting genes for a disease are often translated into functional
modules (categories enriched with the interesting genes), by tools
such as DAVID [3], GO-2D [4] and others [5,6]. However, most of these
tools interpret the interesting genes by ﬁnding isolated functional
modules, providing no further information about their cooperative
effects.
Recently, based on different assumptions, many computational
methods have been designed for studying coordination (also termed
interaction, crosstalk or interplay) relations of functions. Usually, two
functions are deﬁned as a coordinated function pair if they are densely
connected by some relations such as co-expressions of genes [7],
physical or genetic interactions of proteins [8,9] or others [10].
However, most current methods fail to exploit one interesting and
important type of functional coordination regulated by multi-function
genes which exist universally in biological systems. Obviously, the
dysfunction of such multi-function genes may lead to co-deregulationience and Technology, Harbin
83207187.
ll rights reserved.of multiple functions responsible for some diseases [11]. For example,
CDKN1B (cyclin-dependent kinase inhibitor 1B) possesses multiple
functions such as differentiation, apoptosis and cell–cell adhesion [11]
and its dysfunction may deregulate these functions, leading to cancer
[11]. As another example, APC (adenomatosis polyposis coli) plays
roles in several fundamental cellular processes, including cell
adhesion and migration, organization of the actin and microtubule
networks, spindle formation and chromosome segregation. Deregula-
tion of these processes caused by mutations in APC is implicated in the
initiation and expansion of colon cancer [12].
It is reasonable to assume that if the deregulation of two functions
is responsible for inducing a disease, then the genes simultaneously
involved in both functions may be more likely to be disease genes,
which can be used as a clue for ﬁnding function pairs coordinately
contributing to the disease. Here, in this paper, we proposed an
approach to ﬁnd such function pairs for a complex disease using
multi-function disease genes. By analyzing a list of highly reliable
cancer genes, we found many function pairs whose co-deregulation
might be responsible for cancer. Then, based on protein–protein
interaction [2] data and cancer genome mutation data, we found
strong statistical evidences supporting that the coordinated function
pairs identiﬁed by multi-function genes are highly likely to be co-
deregulated by othermolecular changes in cancer, such as dysfunction
of pivot genes [9] or co-mutation of genes between functions. Besides
suggesting new hints for the heterogeneous mechanisms of cancer,
such statistically detectable evidences strongly support that the
obtained function pairs may truly be co-deregulated in cancer. Finally,
to show the proposedmethod can also be used to study other diseases,
95W. Ma et al. / Genomics 94 (2009) 94–100we identiﬁed coordinated function pairs separately for two subtypes
of cardiomyopathy and found a certain consistency of the two
subtypes at the functional coordination level.
Results
CO-function pairs identiﬁed by multi-function disease genes for cancer
As demonstrated in Figs. 1A and B, we deﬁned two functions as a
coordinated function pair (referred to as a CO-function pair for short)
if the disease gene ratio in their overlapped genes is signiﬁcantly
higher than the disease gene ratio in either of the two functions. By
analyzing a list of cancer genes obtained from the Census database
[13], with 10% FDR level (see Materials and methods), we found 86
CO-function pairs involving 61 functions for cancer (see Supplemen-
tary Table S1). For example, “cell cycle checkpoint” and “DNA repair”
were identiﬁed as a CO-function pair because the ratio of cancer genes
increased to 50% in their overlapped gene set, from 23% and 18%
respectively in the two functions. Fig. 1C shows that, for each CO-
function pair, the overlapped genes with multiple functions are much
more likely to be cancer genes than the other genes in the two
functions. We highlight that our method is able to discover someFig. 1. CO-function pairs with increased disease gene ratios. (A) A CO-function pair.
Genes with both functions in a CO-function pair (F1 and F2) may be more likely to be
disease genes, and thus the disease gene ratio in the overlapped set will increase
signiﬁcantly. (B) A non CO-function pair. If F1 and F2 play independently for a disease,
then the disease gene ratio in their overlapped genes will not increase. (C) Cancer gene
ratio distributions in CO-function pairs. Along the transverse axis, the 86 CO-function
pairs for cancer are ranked according to the ascending orders of the cancer gene ratios in
theirs overlapped sets. For each point in the transverse axis, three dots with different
colors represent the overlapped part and non-overlapped part of the two functions of a
CO-function pair, respectively. It shows that for each pair, genes in the overlapped set
contribute more to cancer.important functions, though not enriched with cancer genes in
general, contributing to cancer by mainly a subset of multi-function
genes while the other genes in the functions are less relevant to the
disease. For example, though “cell adhesion” is not enriched with
cancer genes (p=0.66 by hypergeometric test), it may contribute
greatly to cancer by cooperating with other functions such as
“negative regulation of cell proliferation”. Notably, the cancer gene
ratio is only 3% in “cell adhesion” and 8% in “negative regulation of cell
proliferation”. However, the cancer gene ratio in the genes with both
functions is as high as 35%, indicating this subset of genes may play
important roles in cancer through these two functions. On the
contrary, the conventional enrichment methods neglect the fact that
genes in the same function are heterogeneous in contributing to
disease and thus cannot detect the special roles of multi-function
genes.
Then,we took twomulti-function genes, ATM (ataxia telangiectasia
mutated) and P53 (TP53, tumor protein p53), as examples to illustrate
how multi-function genes play functional coordinator roles in cancer.
ATM was found to be involved in three CO-function pairs: j “response
to radiation” and “DNA repair”; k “response to abiotic stimulus” and
“cell cycle”; and l “DNA repair” and “cell cycle checkpoint”. As shown in
Fig. 2A, in response to radiation or other abiotic stimulus that lead to
DNA damage, ATM actives CHK2 (CHEK2) by phosphorylation [14,15],
subsequently stimulating P53 signaling pathway to initiate cell cycle
arrest and DNA repair which are important in preventing cancer
when DNA damage happens [16]. Losing the ability of transferring the
DNA damage signal to P53 by dysfunction of ATM can lead to the
defects of cell cycle arrest and DNA repairs, which subsequently lead to
cancer [17]. As another example, P53 was found to be involved in
ﬁve CO-function pairs: j “response to DNA damage stimulus” and
“induction of apoptosis”, k “regulation of transcription from RNA
polymerase II promoter” and “cell cycle process”, l “regulation of
transcription from RNA polymerase II promoter” and “DNA repair”,
m “regulation of transcription from RNA polymerase II promoter” and
“induction of apoptosis”, and n“DNA repair” and “regulation of
apoptosis”. These ﬁndingsmatch well with the mechanisms described
in the “KEGG: P53 signaling pathway” (Fig. 2B): in response to DNA
damage stimulus, P53 is activated to transcribe its targets that medi-
ate cell cycle, DNA repair and apoptosis. It is reported that the muta-
tion hot spots of P53 are involved in DNA binding [18] which can
lead to a defect in transcription activity [19] and subsequently
deregulation of cell cycle arrest, DNA repair and apoptosis in many
tumors [20]. Thus, by studying these CO-function pairs, we can get a
clear insight that both ATM and P53 may play as coordinators of “cell
cycle progression”, “DNA repair”, “apoptosis”, and “in response to DNA
damage”.
Finally, we note that the proposed method can also be applied to
study the coordination between biological pathways derived from
other data sources such as KEGG [21]. For example, based on KEGG, we
found that “P53 signaling pathway”may play coordinately with most
of the cancer pathways described in KEGG. Many other pathway pairs
coordinately playing in cancer were also revealed, such as “Wnt
signaling pathway” and “Jak-STAT signaling pathway”. To facilitate
using these results, all the obtained cancer coordinated KEGG pathway
pairs are provided in Supplementary Table S2.
CO-function network of cancer
The CO-function network was constructed by connecting the two
functions with an edge in each identiﬁed CO-function pair. By
presenting the attributes of the CO-function pairs in the network,
we can get a clear view of all the CO-function pairs and ﬁnd the most
interesting ones (see Fig. 3). In this network, the top three hubs most
frequently linked with others are “cell adhesion”, “regulation of
transcription from RNA polymerase II promoter” and “negative
regulation of cell proliferation”. Furthermore, viewing from the
Fig. 2. CO-function pairs and multi-function genes explained by “KEGG:P53 signaling pathway”. The red dashed lines mark some CO-function pairs found by our method. Genes
colored by purple are discussed in detail in the text. (A) ATM plays its roles in inducing cancer by deregulating “cell cycle arrest” and “DNA repair” through the P53 signaling pathway.
(B) P53 plays its multiple functions by regulating the transcription of different downstream genes.
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involving “cell adhesion” are highly signiﬁcant, consolidating that
“cell adhesion” coordinates with many other functions in contributing
to cancer [22]. However, as mentioned above, “cell adhesion” is not
enriched with cancer genes and will be undetectable by conventional
enrichment analysis methods.
Then, we analyzed the top three most signiﬁcant CO-function pairs
(see Table 1 and Fig. 3).
(1) First, the most signiﬁcant function pair is “cytoskeleton orga-
nization and biogenesis” and “negative regulation of cell prolifera-
tion”where the cancer gene ratios are 6% and 8% respectively, while
the ratio in their overlapped genes increases to 46% (p-value
7.9×10−5). The co-dysfunction of these two functions in inducing
cancer was reported previously [23]. For example, mutations of
APC can lead to the accumulation of β-catenin (CTNNB1) causing
changes in “cytoskeletal organization” and “proliferation” respon-
sible for cancer [23]. Thus, the deregulation of the coordination
between “cytoskeleton organization” and “cell proliferation” in
inducing cancer warrants further investigation.
(2) The second CO-function pair is “protein complex assembly”
and “DNA metabolic process”. The cancer gene ratios are 10% and
11% separately in these two functions, while the ratio in the
overlapped set increases to 55% (p-value=3.5×10−4). “Protein
complex assembly”, including protein tetramerization, protein
homooligomerization and docking [2], is critical for the activation
of proteins. For example, tetramerization is the active conforma-
tion of P53 and is critically required for the stimulation of DNA
damage [24]. Mutations in tetramerization domain causing the
dysfunction of P53 can lead to inactive for DNA binding in DNA
repair (a kind of “DNA metabolic process”) and subsequently
cancer [24].
(3) Finally, the third CO-function pair is “cell cycle process” and
“regulation of transcription from RNA polymerase II promoter”, in
both of which the cancer gene ratio is 9%, while the ratio in their
overlapped set increases to 46% (p-value=4.0×10−4). As men-
tioned above in the P53 signaling pathway, mutated P53 gene may
play its role in cancer by deregulating its transcriptional target
genes affecting cell cycle process. Many other evidences suggestingthe roles of these two coordinated functions in cancer can be found
in [25].
Co-deregulation of CO-function pairs by different molecular changes
in cancer
As discussed above, the CO-function pairs identiﬁed by multi-
function genes may play important roles in cancer. Similarly to the
effects of the dysfunction of multi-function genes, the co-deregula-
tion of the obtained function pairs could also be carried by some
other molecular changes, such as by the dysfunction of pivot genes
densely linked to both functions [9] or the co-mutation of gene pairs
between the two functions (see Fig. 4). For example, E2F1 (E2F
transcription factor 1) was found to be a pivot gene of the CO-
function pair “response to radiation” and “regulation of apoptosis”.
As shown in Fig. 2, in response to the DNA damage induced by
radiation, ATM activates E2F1 which can subsequently promote P53
induced apoptosis [15,26]. In addition, E2F1 may also play a role in
the activation of ATM [26]. Thus, dysfunction of E2F1 may play a
pivot role in co-deregulating the two functions, subsequently leading
to cancer.
If the co-deregulation of two functions is truly responsible for
cancer, then the pivot genes as coordinators of the two functions may
bemore likely to be cancer genes. Indeed, among the 118 distinct pivot
genes identiﬁed for all the 86 CO-function pairs, 17 are known cancer
genes which are signiﬁcantly more than expected by random chance
(hypergeometric test p-value=5.9×10−7). Next, we show that genes
between the two functions of a CO-function pair tend to mutate
together in cancer, which might be another way of co-deregulation of
the obtained CO-function pairs in cancer. From all the 59,340 pairs
formed by the 345 mutated genes in the cancer mutation data under
this study, we found a total of 59 signiﬁcantly co-mutated gene pairs
in cancer samples (shown in Supplementary Table S3). In all the 59
co-mutated gene pairs, 14 pairs are between the functions in the CO-
function pairs, which are signiﬁcantly more than expected by random
chance (hypergeometric test p-value=0.02). Thus, the found CO-
function pairs tend to be co-deregulated by the co-mutation of gene
pairs in cancer. The above results suggest that the co-deregulation of
the CO-function pairs may truly contribute to cancer.
Fig. 3. The CO-function network of the CO-function pairs. The CO-function network was constructed by connecting every two functions in each of the identiﬁed CO-function pairs
with an edge. Of all the 86 identiﬁed CO-function pairs, 83 pairs involving 56 functions (nodes) are connected together in the network. The node size is proportional to the degree of
the node in the network and the color depth is proportional to the cancer gene ratio in this node. The thickness of an edge is proportional to the signiﬁcance level (reciprocal of the p-
value) of the coordination between the two functions linked by the edge. The nodes and edges indicated by red arrows are discussed in detail in the text.
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linked receptor protein signaling pathway” and “protein amino acid
phosphorylation” that involves multi-function genes, pivot genes
and co-mutated gene pairs. As shown in Fig. 4, the cancer gene
ratios in the two functions are 9.6% and 7.0%, respectively, while the
ratio in their overlapped set increases to 21% (p-value=1.9×10−2).Table 1
The three most signiﬁcant CO-function pairs for cancer.
CO-function pair Ratio p-value
Cytoskeleton organization
and biogenesis
Negative regulation of
cell proliferation
(6%, 8%, 46%)a 7.9×10−5
(6/13)b
Protein complex assembly DNA metabolic process (10%, 11%, 55%)a 3.5×10−4
(6/11)b
Cell cycle process Regulation of transcription
from RNA polymerase II
promoter
(9%, 9%, 46%)a 4.0×10−4
(6/13)b
a The three numbers are the cancer gene ratios in functions 1 and 2 and their
overlapped gene set respectively.
b (C/A): “C” is the number of cancer genes in the overlapped gene set and “A” is the
number of all the genes in the overlapped gene set.There are 7 (21%) cancer genes in all the 33 multi-function genes,
6 (23%) cancer genes in the 26 pivot genes and 1 (50%) cancer
gene in the 2 genes within 1 co-mutated gene pair. This high
prevalence of cancer genes in multi-function genes, pivot genes
and co-mutated genes of the CO-function may suggest to us new
approaches of predicting cancer genes and providing their
candidate cancer mechanisms for further experimental validation.
To support this conjecture, for this CO-function pair, in addition to
the above cancer genes in the Census database, we found 8 (24%)
in the 33 multi-function genes, 5 (19%) in the 26 pivot genes and 1
(50%) in the 2 co-mutated genes that are deﬁned as cancer genes
in another four cancer gene databases [27–30]. Here, we termed
these genes as candidate cancer genes (see Fig. 4). For example,
IGF1R (insulin-like growth factor 1 receptor), possessing both
functions of the CO-function pair, plays roles in mediating of the
signaling pathways by regulating its downstream proteins [31],
which subsequently regulate important cancer processes such as
apoptosis, growth, proliferation and differentiation [31,32]. So,
IGF1R may be a cancer gene whose dysfunction may induce cancer
by reregulating this CO-function pair [33]. This example suggests
the obtained CO-function pairs can provide valuable information
for predicting cancer genes and simultaneously their mechanisms
in inducing cancer.
Fig. 4.Multi-function genes, pivot genes and co-mutated genes for a CO-function pair. F1 and F2 represent “protein amino acid phosphorylation” and “enzyme linked receptor protein
signaling pathway”, respectively. The color depth is proportional to the cancer gene ratio in F1, F2, the multi-function genes and the pivot genes. Note that cancer genes in Census and
candidate cancer genes in other four cancer gene databases [27–30] are also discriminated by different colors. Pivot genes of F1 and F2 are indicated by PPI links to F1 and F2. Two co-
mutated genes separately belong to F1 and F2 are linked by red dashed lines. IGF1R gene indicated by a red arrow is discussed in detail in the text.
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The proposed method can also be used to model coordinated
functions for other complex diseases with multi-function disease
genes. For illustration, we additionally studied and compared two
subtypes of cardiomyopathy: dilated cardiomyopathy (DCM) and
hypertrophic cardiomyopathy (HCM) with 18 and 15 disease genes
(with GO “Biological Process” annotation) obtained from OMIM
database [34], respectively. Using the same parameter setting as
for cancer described above, we found 3 and 19 coordinated function
pairs for DCM and HCM, respectively (see Supplementary Tables S4
and S5). Interestingly, although only 5 of the 18 DCM disease genes
are shared by 15 HCM disease genes, all the 3 coordinated function
pairs for DCM are shared by HCM. This result suggests a certain
consistency of the two subtypes at the functional coordination level,
supporting a previous report that the two distinct subtypes may
share some key pathogenic mechanisms such as defects in the
cardiac sarcomere [35].
As an example, we further analyzed a coordinated function pair
“muscle development” and “muscle contraction” shared by DCM and
HCM. Although DCM and HCM both involve dysfunction of this CO-
function pair, the divergence of DCM and HCM is caused by affecting
different aspects of the two functions. It has been suggested that
impaired force transmission from the sarcomere to the surrounding
syncytium (muscle contraction) may predispose affected myocytes to
mechanical injury and cumulative cell death, secondary interstitial
ﬁbrosis, and cardiac dilation (muscle development), resulting in DCM
[36–38]. On the other hand, HCM may be caused by the defects in
force generation and impaired contractile performance (muscle
contraction), which may lead to HCM through the compensatory
hypertrophy remodeling of the heart (muscle development) [37,38].
We note that knowledge about themolecular mechanisms that trigger
changes in cardiomyopathy is currently deﬁcient [37], and thus manyprominent functional coordination relations identiﬁed for it may
warrant further biological investigations.
Discussion
The phenomenon that functions play coordinately in biological
systems has been revealed by many wet-lab experiments [39]. In this
paper, we proposed an approach to ﬁnd coordinated function pairs
involving multi-function disease genes. By analyzing a list of cancer
genes based on GO or KEGG, we found many function pairs whose co-
deregulation may induce cancer. Additionally, we found that the
obtained CO-function pairs are highly likely to be co-deregulated in
cancer by other molecular changes, including the dysfunction of pivot
genes or co-mutation of genes between the two functions in each pair.
This result suggests new hints for the heterogeneous mechanisms of
cancer. As illustrated in the Results section, the multi-function genes,
pivot genes and co-mutated genes, involved in the obtained CO-
function pairs, can provide valuable information for ﬁnding novel
cancer genes and their mechanisms in cancer. We additionally studied
two subtypes of cardiomyopathy and identiﬁed some prominent
disease-speciﬁc coordinated functions, showing that the proposed
method can also be used to study other diseases.
For a given disease gene list, most current bioinformatics tools
designed for ﬁnding functional modules enriched with the disease
genes provide no information about functional coordination.
Moreover, our proposed method can ﬁnd some important dis-
ease-related pathways not enriched with disease genes, while such
functions are undetectable by traditional enrichment analysis
methods. For example, we found that “cell adhesion” is not
enriched with cancer genes but it is the function most frequently
cooperating with other functions in cancer. A resent study also
reported that some causal functions of a disease are not necessarily
enriched with the disease genes [40]. Notably, many functions in
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related pathways. However, this does not mean the obtained CO-
function pairs are too general to gain insights into the biological
mechanisms of cancer. Oppositely, our ﬁndings highlight the
collaboration between the pathways, rather than the individual
pathways. To our knowledge, many prominent CO-function pairs
obtained for the two diseases under this study have not been fully
investigated and they would provide important hints for designing
biological experiments to study the disease mechanisms at the
functional collaboration level.
Our proposed method is speciﬁcally designed for ﬁnding coordi-
nated function pairs involving multi-function disease genes.
Obviously, it is important to develop this method to ﬁnd other types
of coordinated function pairs contributing to diseases. A possible
approach for this extension is to integrate some functional links such
as gene co-expression [7], protein physical and genetic interactions
[8,9] and others [10], which warrant our future researches for
revealing disease mechanisms.
Materials and methods
Data description
Based on the GO “Biological Process” ontology (released March 28,
2008) [2], we analyzed functions annotated with 15 to 500 genes,
excluding the low-qualiﬁed annotation data denoted as IEA (Inferred
from Electronic Annotation) and ND (No biological Data available)
[41]. We also analyzed the pathways deﬁned in the KEGG database
[21] (downloaded in Dec. 1, 2008), which includes 214 signal and
metabolic pathways.
The cancer genes were derived from the Cancer Gene Census
database (referred to as the Census database for short) [13], which is
themost frequently used cancer gene databasewith high quality. For a
total of 367 cancer genes in the Census database, 261 with GO
“Biological Process” annotation were analyzed in this study. The 15
and 18 disease genes for HCM and DCM respectively were obtained
from the OMIM database [34].
The gene mutation data was integrated from four genome-wide
somatic mutation screen datasets for a total of 2905 genes in 125
tumor samples of 4 cancer types [42–44]. We ﬁltered out those genes
mutated in only one sample and analyzed the remaining 709 genes.
Our dataset choice tends to bias the co-occurring mutation gene pairs
shared by various cancers, rather than gene pairs for a speciﬁc cancer
type.
The human PPI data was derived from the HPRD database (Release
6) [45]. After removing self-interactions, 34,560 interactions among
9261 distinct human proteins were remaining for analysis.
Finding CO-function pairs
If the co-deregulation of two functions is responsible for inducing a
disease, then the genes with both functions may be more likely to be
disease genes. Based on this assumption, we deﬁned two functions (F1
and F2) as a coordinated function pair (referred to as a CO-function
pair) if the disease gene ratio (r0) in the overlapped gene set
(O=F1∩F2) of the two functions is signiﬁcantly higher than both of
the disease gene ratios (rF1 and rF2 ) in the two functions (demon-
strated in Figs. 1A, B). Statistically, the null hypothesis (H0) and the
alternative hypothesis (H1) are as follows
H0 : rO = maxðrF1 ; rF2 Þ;H1 : rO N maxðrF1 ; rF2 Þ:
Suppose that the disease gene ratio in the overlapped genes of a
function pair is r0=k/n where k is the number of disease genes
among n overlapped genes of the two functions, and in one of the two
functions which has the higher disease gene ratio, there areM diseasegenes among a total of N genes. Then, the probability (p-value) of
obtaining the disease gene ratio r0=k/n in the overlapped genes of
the two functions by random chance was estimated by the
hypergeomertic distribution model [46] as follows
p = 1−
Xk−1
i=0
M
i
 
N − M
n − i
 
N
n
  :
Considering the multiple testing problem, we applied a re-
sampling based YB-FDR control procedure proposed by Yekutieli
and Benjamini [47] because the test statistics are highly correlated and
the number of tests for all the combinations of two functions in GO is
extremely large. We did not use the BH-FDR approach proposed by
Benjamini and Hochberg [48] because it assumes that all the test
statistics are independent [47,49], which will yield very conservative
results [6,49] if the test statistics are correlated and the number of
tests is very large. The detailed procedure of the computationally
intensive re-sampling procedure for YB-FDR control used in this study
is described in Supplementary methods. Under a given FDR threshold,
if two functions with ancestor–offspring relationship were both
paired with a function, then the pair with the ancestor function was
removed.
Finding pivot proteins and co-mutated gene pairs
A proteinwas deﬁned as a pivot protein for a CO-function pair if its
PPIs with both the non-overlapping parts of the two functions are
more frequent than expected by random chance [9]. The statistical
signiﬁcance was evaluated by a hypergeometric test (p≤0.01).
Then, for ﬁnding co-mutated gene pairs in cancer based on the
mutation data of 709 genes in 125 cancer samples, we calculated the
mutual information (MI) value [50] of a gene pair (i,j) as
MI i;jð Þ =
X
xaX
X
yaY
p x;yð Þ log p x; yð Þ
pi xð Þpj yð Þ
:
pi(x) or pj(y) is the probability of X=x or Y=y. Here, x=1 or 0 if
gene i is mutated or not in a sample, and for y=1 or 0 if gene j is
mutated or not in a sample. p(x,y) is the joint probability of X=x and
Y=y.
After computing the MI values for all the gene pairs, we
constructed the null distribution of random MI values by computing
the MI values for gene pairs from 1000 sets of random mutation
data produced by independently permuting each gene's mutation
status in the samples while keeping its mutation times unchanged.
If a pair of genes have a signiﬁcantly high MI value, controlled by
FDR=10% (see details in Supplementary methods), they were
deﬁned as a co-mutated gene pair.
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